n Cardiovascular Journal of South Africa - Reflections on the withdrawal of rofecoxib : editorial

Volume 16, Issue 1
  • ISSN : 1680-0745



Extracted from text ... CARDIOVASCULAR JOURNAL OF SOUTH AFRICA Vol 16, No. 1, January/February 2005 5 Reflections on the withdrawal of rofecoxib And therefore never send to know for whom the bell tolls; it tolls for thee. John Donne Rofecoxib was launched in 1999. Rofecoxib, a cyclooxygenase- 2-specific (COX-2) inhibitor, revolutionised the nonsteroidal anti-inflammatory drug (NSAID) treatment of rheumatoid arthritis because its use was associated with a significantly lower incidence of gastro-intestinal bleeding than when using a conventional NSAID, naproxen. This was shown in the VIGOR (VIOXX Gastrointestinal Outcomes Research) trial.1 Very soon, another COX-2 inhibitor, celecoxib, made its commercial appearance and it has ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error